{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-247692","form_type":"8-K","ticker":"SLN","cik":"0001479615","company_name":"Silence Therapeutics plc","filed_at":"2025-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.496693+00:00","generated_at":"2026-05-17T02:29:27.911610+00:00","sec_items":["8.01","2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silence Therapeutics completes SANRECO Phase 2 enrollment for divesiran in PV; topline data expected 3Q'26","bullets":["48 phlebotomy-dependent PV patients enrolled in global, randomized, double-blind, placebo-controlled study.","Primary endpoint: proportion maintaining HCT <45% without phlebotomies between weeks 18 and 36.","Phase 2 evaluates two dosing intervals (Q6W and Q12W); Phase 1 showed potential with Q6W dosing.","Topline results anticipated in the third quarter of 2026.","CEO cites divesiran as first-in-class siRNA targeting TMPRSS6 for significant unmet need in PV."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-247692","json":"https://secwatch.observer/filing/0001193125-25-247692.json","markdown":"https://secwatch.observer/filing/0001193125-25-247692.md","text":"https://secwatch.observer/filing/0001193125-25-247692.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525247692/0001193125-25-247692-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525247692/sln-20251023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:29:27.911610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}